Erythropoietin	erythropoietin	O	O	O	O
restores	restores	O	O	O	O
the	the	O	O	O	O
anemia-induced	anemia-induced	O	O	O	O
reduction	reduction	O	O	O	O
in	in	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
cytotoxicity	cytotoxicity	O	O	OTHERS	I
in	in	O	O	O	O
rat	rat	O	O	O	O
tumors	tumors	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
aim	aim	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
examine	examine	O	O	O	O
the	the	O	O	O	O
impact	impact	O	O	O	O
of	of	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
prevention	prevention	O	O	O	O
by	by	O	O	O	O
recombinant	recombinant	O	O	O	O
human	human	O	O	O	O
erythropoietin	erythropoietin	O	O	O	O
(	(	O	O	O	O
rHuEPO	rhuepo	O	O	O	O
)	)	O	O	O	O
treatment	treatment	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
cytotoxicity	cytotoxicity	O	O	OTHERS	I
of	of	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
solid	solid	O	O	O	O
experimental	experimental	O	O	O	O
tumors	tumors	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Anemia	anemia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
induced	induced	O	O	O	O
using	using	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
50	50	O	O	O	O
mg/kg	mg/kg	O	O	O	O
i.v	i.v	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
resulting	resulting	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
long-lasting	long-lasting	O	O	O	O
reduction	reduction	O	O	O	O
(	(	O	O	O	O
30	30	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
hemoglobin	hemoglobin	O	O	O	O
concentration	concentration	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
a	a	O	O	O	O
second	second	O	O	O	O
group	group	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
prevented	prevented	O	O	O	O
by	by	O	O	O	O
rHuEPO	rhuepo	O	O	O	O
(	(	O	O	O	O
1000	1000	O	O	O	O
IU/kg	iu/kg	O	O	O	O
)	)	O	O	O	O
administered	administered	O	O	O	O
s.c	s.c	O	O	O	O
.	.	O	O	O	O

three	three	O	O	O	O
times/week	times/week	O	O	O	O
starting	starting	O	O	O	O
7	7	O	O	O	O
days	days	O	O	O	O
before	before	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
application	application	O	O	O	O
.	.	O	O	O	O

Four	four	O	O	O	O
days	days	O	O	O	O
after	after	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
,	,	O	O	O	O
tumors	tumors	O	DISEASE	OTHERS	I
(	(	O	O	O	O
DS-sarcoma	ds-sarcoma	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
rat	rat	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
implanted	implanted	O	O	O	O
s.c	s.c	O	O	O	O
.	.	O	O	O	O
onto	onto	O	O	O	O
the	the	O	O	O	O
hind	hind	O	O	O	O
food	food	O	O	O	O
dorsum	dorsum	O	O	O	O
.	.	O	O	O	O

Neither	neither	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
nor	nor	O	O	O	O
rHuEPO	rhuepo	O	O	O	O
treatment	treatment	O	O	O	O
influenced	influenced	O	O	O	O
tumor	tumor	O	DISEASE	OTHERS	I
growth	growth	O	O	O	O
rate	rate	O	O	O	O
per	per	O	O	O	O
se	se	O	DISEASE	OTHERS	I
.	.	O	O	O	O

When	when	O	O	O	O
tumors	tumors	O	DISEASE	OTHERS	I
were	were	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
60	60	O	O	O	O
mg/kg	mg/kg	O	O	O	O
i.p	i.p	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
5	5	O	O	O	O
days	days	O	O	O	O
after	after	O	O	O	O
implantation	implantation	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
growth	growth	O	O	O	O
delay	delay	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
subsequent	subsequent	O	O	O	O
regrowth	regrowth	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
tumors	tumors	O	DISEASE	OTHERS	I
was	was	O	O	O	O
observed	observed	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
group	group	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
growth	growth	O	O	O	O
delay	delay	O	O	O	O
was	was	O	O	O	O
significantly	significantly	O	O	O	O
shorter	shorter	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
nonanemic	nonanemic	O	O	O	O
controls	controls	O	O	O	O
(	(	O	O	O	O
13.3	13.3	O	O	O	O
days	days	O	O	O	O
versus	versus	O	O	O	O
8.6	8.6	O	O	O	O
days	days	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
group	group	O	O	O	O
where	where	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
prevented	prevented	O	O	O	O
by	by	O	O	O	O
rHuEPO	rhuepo	O	O	O	O
treatment	treatment	O	O	O	O
,	,	O	O	O	O
growth	growth	O	O	O	O
delay	delay	O	O	O	O
was	was	O	O	O	O
comparable	comparable	O	O	O	O
with	with	O	O	O	O
that	that	O	O	O	O
of	of	O	O	O	O
nonanemic	nonanemic	O	O	O	O
controls	controls	O	O	O	O
(	(	O	O	O	O
13.3	13.3	O	O	O	O
days	days	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
results	results	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
chemotherapy-induced	chemotherapy-induced	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
reduces	reduces	O	O	O	O
cytotoxicity	cytotoxicity	O	O	OTHERS	I
of	of	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
tumors	tumors	O	DISEASE	OTHERS	I
,	,	O	O	O	O
whereas	whereas	O	O	O	O
correction	correction	O	O	O	O
of	of	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
by	by	O	O	O	O
rHuEPO	rhuepo	O	O	O	O
treatment	treatment	O	O	O	O
(	(	O	O	O	O
epoetin	epoetin	O	O	O	O
alpha	alpha	O	O	O	O
)	)	O	O	O	O
increases	increases	O	O	O	O
the	the	O	O	O	O
sensitivity	sensitivity	O	O	O	O
,	,	O	O	O	O
probably	probably	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
result	result	O	O	O	O
of	of	O	O	O	O
an	an	O	O	O	O
improved	improved	O	O	O	O
oxygen	oxygen	CHEMICALS	O	OTHERS	I
supply	supply	O	O	O	O
to	to	O	O	O	O
tumor	tumor	O	DISEASE	OTHERS	I
tissue	tissue	O	O	O	O
.	.	O	O	O	O

